Cytokinetics Shares Outstanding 2010-2024 | CYTK

Cytokinetics shares outstanding for the quarter ending December 31, 2024 were 0.112B, a 2.51% increase year-over-year.

  • Cytokinetics 2024 shares outstanding were 0.112B, a 0% decline from 2024.
  • Cytokinetics 2024 shares outstanding were 0.112B, a 16.01% increase from 2023.
  • Cytokinetics 2023 shares outstanding were 0.097B, a 0% decline from 2023.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.

Cytokinetics Shares Outstanding 2010-2024 | CYTK

  • Cytokinetics 2024 shares outstanding were 0.112B, a 0% decline from 2024.
  • Cytokinetics 2024 shares outstanding were 0.112B, a 16.01% increase from 2023.
  • Cytokinetics 2023 shares outstanding were 0.097B, a 0% decline from 2023.

Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Related Stocks
Company NameMarket
Cap
AstraZeneca (AZN)$228.9B
Amgen (AMGN)$158.1B
Gilead Sciences (GILD)$134.2B
Vertex Pharmaceuticals (VRTX)$121.1B
Bristol Myers Squibb (BMY)$111.6B
CSL (CSLLY)$80.7B
GSK (GSK)$75.7B
Regeneron Pharmaceuticals (REGN)$75B
Argenex SE (ARGX)$38.9B
Alnylam Pharmaceuticals (ALNY)$32.4B
BioNTech SE (BNTX)$28.7B
BeiGene (ONC)$23.2B
Biogen (BIIB)$20B
Illumina (ILMN)$16.3B
Insmed (INSM)$15B
Genmab (GMAB)$14.5B
Genmab (GNMSF)$14.4B
Moderna (MRNA)$13.8B
Intra-Cellular Therapies (ITCI)$13.7B
Incyte (INCY)$13.6B
BioMarin Pharmaceutical (BMRN)$12.5B
Swedish Orphan Biovitrum (BIOVF)$10.9B
Bio-Techne Corp (TECH)$10.4B
Vaxcyte (PCVX)$10.4B
Sarepta Therapeutics (SRPT)$10.2B
Exelixis (EXEL)$9.8B
Ascendis Pharma (ASND)$9.4B
Exact Sciences (EXAS)$9.3B
Bio-Rad Laboratories (BIO.B)$8.7B
QIAGEN (QGEN)$8.7B